Decreased FOXF2 mRNA Expression Indicates Early-Onset Metastasis and Poor Prognosis for Breast Cancer Patients with Histological Grade II Tumor

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kong, Peng Zhou ^a   Yang, Fan ^a   Li, Lin ^a   Li, Xiao Qing ^a,b   Feng, Yu Mei ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; DISEASE FREE SURVIVAL; FEMALE; FOXF2 GENE; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TIME FACTORS;

EID: 84876443811     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061591     Document Type: Article

References (40)

1. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, et al. (1998) Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77: 621-626.
2. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR, (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91: 2012-2017.
3. Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, et al. (2011) Endocrine therapy of breast cancer. Curr Med Chem 18: 513-522.
4. Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M, (2009) HER-2 as a target for breast cancer therapy. Clin Cancer Res 15: 1848-1852.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
7. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398.
8. Badve S, Nakshatri H, (2009) Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 62: 6-12.
9. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, et al. (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15: 2302-2310.
10. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, et al. (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53.
11. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI, (2011) The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol 28: 745-752.
12. Foulkes WD, Smith IE, Reis-Filho JS, (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948.
13. Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, et al. (2006) Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 24: 4245-4253.
14. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158-5165.
15. Katoh M, Katoh M, (2004) Human FOX gene family (Review). Int J Oncol 25: 1495-1500.
16. Carlsson P, Mahlapuu M, (2002) Forkhead transcription factors: key players in development and metabolism. Dev Biol 250: 1-23.
17. Hannenhalli S, Kaestner KH, (2009) The evolution of Fox genes and their role in development and disease. Nat Rev Genet 10: 233-240.
18. Le Lay J, Kaestner KH, (2010) The Fox genes in the liver: from organogenesis to functional integration. Physiol Rev 90: 1-22.
19. Lo PK, Lee JS, Liang X, Han L, Mori T, et al. (2010) Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res 70: 6047-6058.
20. Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, et al. (2007) FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer 120: 1013-1022.
21. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, et al. (2007) FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res 13: 4415-4421.
22. Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, et al. (2008) Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 61: 327-332.
23. Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, et al. (2010) FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 70: 3870-3876.
24. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, et al. (2007) Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A 104: 10069-10074.
25. Wang T, Tamakoshi T, Uezato T, Shu F, Kanzaki-Kato N, et al. (2003) Forkhead transcription factor Foxf2 (LUN)-deficient mice exhibit abnormal development of secondary palate. Dev Biol 259: 83-94.
26. Ormestad M, Astorga J, Landgren H, Wang T, Johansson BR, et al. (2006) Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development 133: 833-843.
27. Aitola M, Carlsson P, Mahlapuu M, Enerback S, Pelto-Huikko M, (2000) Forkhead transcription factor FoxF2 is expressed in mesodermal tissues involved in epithelio-mesenchymal interactions. Dev Dyn 218: 136-149.
28. van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G, (2009) Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int 103: 1574-1580.
29. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, et al. (2011) MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 71: 2926-2937.
30. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J, (2011) GOBO: gene expression-based outcome for breast cancer online. PLoS One 6: e17911.
31. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964.
32. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
33. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214.
34. van der Heul-Nieuwenhuijsen L, Dits N, Van Ijcken W, de Lange D, Jenster G, (2009) The FOXF2 pathway in the human prostate stroma. Prostate 69: 1538-1547.
35. Ormestad M, Astorga J, Carlsson P, (2004) Differences in the embryonic expression patterns of mouse Foxf1 and -2 match their distinct mutant phenotypes. Dev Dyn 229: 328-333.
36. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
37. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
38. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, et al. (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100: 5974-5979.
39. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, et al. (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9: R65.
40. Feng Y, Sun B, Li X, Zhang L, Niu Y, et al. (2007) Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat 103: 319-329.